40. Takayasu arteritis Clinical trials / Disease details
Clinical trials : 24 / Drugs : 40 - (DrugBank : 18) / Drug target genes : 23 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05151848 (ClinicalTrials.gov) | January 5, 2022 | 6/11/2021 | Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis | An Open-label,Randomized, Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis | Takayasu Arteritis | Drug: Adalimumab Injection;Drug: Tofacitinib 5 MG | Chinese SLE Treatment And Research Group | NULL | Recruiting | 18 Years | 65 Years | All | 100 | Phase 4 | China |
| 2 | JPRN-jRCT2061210007 | 13/10/2021 | 28/05/2021 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis | Takayasu Arteritis | Ustekinumab Participants will receive IV infusion and SC injection of ustekinumab. Placebo Participants will receive IV infusion and SC injection of matching placebo. Glucorticoid Taper Regimen Glucocorticoid will be administered orally. | Nishikawa Kazuko | NULL | Recruiting | >= 18age old | <= 75age old | Both | 50 | Phase 3 | Japan |
| 3 | NCT04882072 (ClinicalTrials.gov) | September 15, 2021 | 10/5/2021 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis | Takayasu Arteritis | Drug: Ustekinumab;Other: Placebo;Drug: Glucorticoid Taper Regimen | Janssen Pharmaceutical K.K. | NULL | Active, not recruiting | 15 Years | 75 Years | All | 14 | Phase 3 | Japan |
| 4 | NCT05168475 (ClinicalTrials.gov) | July 14, 2021 | 9/12/2021 | Biologics in Refractory Vasculitis | Biologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and Children | Giant Cell Arteritis;Takayasu Arteritis;Cogan Syndrome;Relapsing Polychondritis;Cryoglobulinemic Vasculitis;IgA Vasculitis;Polyarteritis Nodosa;Cutaneous Polyarteritis Nodosa;Primary Angiitis of Central Nervous System | Biological: Rituximab;Biological: Infliximab;Biological: Tocilizumab | Cambridge University Hospitals NHS Foundation Trust | NULL | Recruiting | 5 Years | N/A | All | 140 | Phase 2 | United Kingdom |
| 5 | NCT04564001 (ClinicalTrials.gov) | September 2020 | 21/9/2020 | Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis | Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis | Takayasu Arteritis | Drug: Infliximab;Drug: Tocilizumab | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 50 | Phase 2 | NULL |
| 6 | NCT04300686 (ClinicalTrials.gov) | March 1, 2020 | 5/3/2020 | A Pilot Study in Severe Patients With Takayasu Arteritis. | A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA Cohort | Takayasu Arteritis;Tocilizumab;Adalimumab;Treatment | Biological: Tocilizumab;Biological: Adalimumab | Shanghai Zhongshan Hospital | NULL | Recruiting | 14 Years | 100 Years | All | 40 | Phase 4 | China |
| 7 | NCT04299971 (ClinicalTrials.gov) | March 1, 2020 | 5/3/2020 | Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients | Randomized Open-label Study in Mild and Moderate Patients With Takayasu Arteritis Between Methotrexate and Tofacitinib Based on the ECTA Cohort. | Takayasu Arteritis;Methotrexate;Inhibition;Treatment | Drug: Methotrexate Tablets;Drug: Tofacitinib tablet | Shanghai Zhongshan Hospital | NULL | Recruiting | 14 Years | 100 Years | All | 130 | Phase 4 | China |
| 8 | NCT04161898 (ClinicalTrials.gov) | February 4, 2020 | 12/11/2019 | A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu) | Takayasu Arteritis (TAK) | Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: Prednisolone | AbbVie | NULL | Recruiting | 15 Years | N/A | All | 56 | Phase 3 | Argentina;Brazil;China;Japan;Korea, Republic of;Turkey |
| 9 | EUCTR2018-003753-13-FR (EUCTR) | 19/03/2019 | 13/12/2018 | INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis | Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis | Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: RoActemra 20mg/ml Product Name: Tocilizumab INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB Product Name: Infliximab INN or Proposed INN: INFLIXIMAB | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 3 | France | ||
| 10 | NCT03482479 (ClinicalTrials.gov) | February 4, 2019 | 22/3/2018 | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis | Drug: Naltrexone Hydrochloride;Other: Placebo Comparator | University of Pennsylvania | NULL | Recruiting | 18 Years | N/A | All | 36 | Phase 2 | United States |
| 11 | NCT03550781 (ClinicalTrials.gov) | June 1, 2018 | 5/5/2018 | Anti-inflammatory Treatment for Inactive Takayasu Arteritis | Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment? | Takayasu Arteritis;Anti-Inflammatory Agents | Drug: Prednisone, cyclophosphamide | Chinese Academy of Medical Sciences, Fuwai Hospital | NULL | Not yet recruiting | 10 Years | 40 Years | All | 40 | Phase 2/Phase 3 | NULL |
| 12 | NCT03430388 (ClinicalTrials.gov) | January 31, 2018 | 30/1/2018 | Yellow Fever Vaccine in Patients With Rheumatic Diseases | Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area | Systemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile Dermatomyositis | Biological: Yellow Fever vaccine (17D) | University of Sao Paulo General Hospital | NULL | Completed | 2 Years | 60 Years | All | 600 | N/A | Brazil |
| 13 | NCT03096275 (ClinicalTrials.gov) | March 16, 2017 | 13/3/2017 | Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis | Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis | Takayasu Arteritis | Drug: MMF;Drug: CYC;Drug: Glucocorticoids;Drug: MTX;Drug: AZA | Chinese SLE Treatment And Research Group | Peking Union Medical College Hospital | Active, not recruiting | 18 Years | N/A | All | 138 | Phase 3 | China |
| 14 | NCT03192878 (ClinicalTrials.gov) | March 1, 2017 | 9/5/2017 | Infliximab Biosimilar in Takayasu's Arteritis | A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments | Takayasu Arteritis | Drug: Infliximab | Ospedale San Raffaele | NULL | Recruiting | 18 Years | N/A | All | 30 | N/A | Italy |
| 15 | JPRN-UMIN000025940 | 2017/02/07 | 07/02/2017 | Clinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu Arteritis | Clinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu Arteritis - TOCIlizumab treatment for TAKayasu arteritis (TOCI-TAK) | Takayasu arteritis | Intravenous administration of tocilizumab (8mg/kg/month) for up to 12 months | Osaka University | National Cerebral and Cardiovascular Center | Complete: follow-up continuing | 16years-old | 60years-old | Male and Female | 2 | Not selected | Japan |
| 16 | NCT03199183 (ClinicalTrials.gov) | January 1, 2017 | 23/6/2017 | Registration Study of Takayasu's Arteritis in China | Registration Study of Takayasu's Arteritis in China | Takayasu Arteritis | Radiation: PET-CT;Other: laboratory biomarker analysis;Genetic: genetic sequencing | China National Center for Cardiovascular Diseases | NULL | Recruiting | N/A | N/A | All | 1067 | China | |
| 17 | NCT03893136 (ClinicalTrials.gov) | November 1, 2016 | 12/3/2019 | The Registry Study of Takayasu Arteritis in East China | The Cohort Study of East Chinese Takayasu's Arteritis (ECTA-cohort Study) | Takayasu Arteritis;Mechanisms, Defense;Pregnancy Related;Treatment Refusal;Outcome | Biological: Tocilizumab;Drug: Leflunomide | Shanghai Zhongshan Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 1000 | China | |
| 18 | NCT02457585 (ClinicalTrials.gov) | March 2015 | 18/5/2015 | Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis | Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis | Takayasu's Arteritis | Drug: remicade (anti tumor necrosis factor inhibitor) | Seoul National University Hospital | NULL | Recruiting | 18 Years | N/A | All | 11 | Phase 2 | Korea, Republic of |
| 19 | JPRN-JapicCTI-142616 | 02/10/2014 | 23/07/2014 | Phase III Study of MRA-SC in Patients with Takayasu Arteritis | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis | Takayasu Arteritis | Intervention name : tocilizumab (MRA-SC) INN of the intervention : tocilizumab Dosage And administration of the intervention : 162mg/W, SC Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo/W, SC | Chugai Pharmaceutical Co., Ltd. | NULL | complete | 12 | BOTH | 34 | Phase 3 | Japan | |
| 20 | JPRN-UMIN000025943 | 2014/08/07 | 07/02/2017 | Long-term Safety of treatment with tocilizumab in the refractory patients with Takayasu Arteritis | Long-term Safety of treatment with tocilizumab in the refractory patients with Takayasu Arteritis - Long-term ACTemra Investigation for remissION introduction in TAKayasu Arteritits (LACTION-TAK) | Takayasu arteritis | Intravenous administration of tocilizumab (8mg/kg/month) will be performed until December 31st, 2017. | Osaka Unversity | National Cerebral and Cardiovascular Center | Complete: follow-up continuing | 16years-old | 60years-old | Male and Female | 9 | Not selected | Japan |
| 21 | NCT02101333 (ClinicalTrials.gov) | June 10, 2014 | 17/2/2014 | Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis | Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study | TAKAYASU ARTERITIS | Drug: Tocilizumab | Assistance Publique - Hôpitaux de Paris | Chugai Pharmaceutical | Completed | 18 Years | 77 Years | All | 18 | Phase 3 | France |
| 22 | JPRN-UMIN000008812 | 2012/10/01 | 01/10/2012 | Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR) | Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR) - Treatment of LVV and PMR by tocilizumab mono-therapy | Rheumatoid arthritis | tocilizumab monotherapy | Department of Rheumatology & Clinical ImmunologySaitama Medical Center, Saitama Medical Universitity | NULL | Complete: follow-up complete | 16years-old | 80years-old | Male and Female | 40 | Not selected | Japan |
| 23 | JPRN-UMIN000007845 | 2012/05/01 | 01/05/2012 | Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu Arteritis | Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu Arteritis - ACTemra Investigation for remissiON introduction in Takayasu Arteritits (ACTION-TA) | Takayasu arteritis | Intravenous administration of tocilizumab (8mg/kg/month) for 24 months | Department of Cardiovascular Medicine Graduate School of Medicine Osaka University | NULL | Complete: follow-up continuing | 16years-old | 60years-old | Male and Female | 15 | Not selected | Japan |
| 24 | NCT00006055 (ClinicalTrials.gov) | March 2000 | 5/7/2000 | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases | Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation | Fairview University Medical Center | NULL | Active, not recruiting | 1 Year | 55 Years | Both | 10 | N/A | United States |